Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals, LLC
Conjupro Biotherapeutics, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
Pfizer
Pfizer
Prelude Therapeutics
Royal Marsden NHS Foundation Trust
National Cancer Institute (NCI)
Ocellaris Pharma, Inc.
Pfizer
Kezar Life Sciences, Inc.
Regeneron Pharmaceuticals
Takeda
Transgene
Tempus AI
Incyte Corporation
NiKang Therapeutics, Inc.
Pfizer
NYU Langone Health
NuCana plc
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
NRG Oncology
M.D. Anderson Cancer Center
Daiichi Sankyo
Hutchmed
NextCure, Inc.
Elevation Oncology
Kymab Limited
Checkpoint Therapeutics, Inc.
Incyte Corporation
Biomea Fusion Inc.
Maastricht University Medical Center
Deciphera Pharmaceuticals, LLC
Mirati Therapeutics Inc.
Navire Pharma Inc., a BridgeBio company
Boehringer Ingelheim
Pfizer
NantCell, Inc.
NantCell, Inc.
Pfizer
Hospices Civils de Lyon
Pfizer
Turning Point Therapeutics, Inc.
Olympus Corporation of the Americas
Puma Biotechnology, Inc.
NKGen Biotech, Inc.